Get to know our clinical trials

Phase 2, multicohort clinical trial to further characterize the efficacy and safety of ciltacabtagene autoleucel

THE AIM OF THIS STUDY IS TO GATHER FURTHER INFORMATION ON HOW CILTA-CEL WORKS AND ITS SAFETY IN THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, A TYPE OF CANCER. THE STUDY WILL INCLUDE DIFFERENT GROUPS OF PATIENTS, REFERRED TO AS COHORTS.

Dra. Paula Rodríguez Otero, especialista en Hematología, dedicada al mieloma múltiple y el trasplante alogénico – Clínica Universidad de Navarra
Dr. Paula Rodríguez Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE 2, MULTICOHORT STUDY TO FURTHER CHARACTERIZE THE EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL
  • Code EudraCT: 2025-521975-30
  • Protocol number: 68284528MMY2012
  • Promoter: Janssen Cilag SZ
  • Molecule/Drug: Cilta-cel
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION